Literature DB >> 10369196

Management of IgA nephropathy: evidence-based recommendations.

L Nolin1, M Courteau.   

Abstract

The condition known as IgA nephropathy was first identified when Berger observed mesangial staining for IgA in healthy patients with isolated hematuria. These patients often presented with recurrent synpharyngitic hematuria or less frequently with asymptomatic microscopic hematuria and proteinuria. Although initially considered benign, we now recognize it as a common cause of end-stage renal failure. The overall prognosis may be better than suggested in the literature, as patients with mild asymptomatic hematuria are often not biopsied and, therefore, frequently are not included in published articles. We reviewed prospective and retrospective adult studies published after 1976 and analyzed them to produce evidence-based recommendations. Patients with proteinuria over 3 g/day, mild glomerular changes only, and preserved renal function (creatinine clearance over 70 ml/min) should be treated with prednisone. Steroids reduce proteinuria (grade B recommendation) and stabilize kidney function (grade C). The combination of cyclophosphamide, dipyridamole and warfarin should not be used (grade A), nor should cyclosporine A (grade B). In patients with progressive disease (creatinine clearance of less than 70 ml/min), fish oil should be given (grade B). A tonsillectomy could reduce proteinuria and hematuria in those patients with recurrent tonsillitis (grade D). Those with hypertension should be treated promptly with an angiotensin-converting enzyme inhibitor (grade B).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10369196     DOI: 10.1046/j.1523-1755.1999.07008.x

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  18 in total

Review 1.  The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease.

Authors:  Imari Mimura; Masaomi Nangaku
Journal:  Nat Rev Nephrol       Date:  2010-09-28       Impact factor: 28.314

2.  Atypical triad of IgA nephropathy: reversible acute kidney injury, gross hematuria, and severe bilateral flank pain.

Authors:  Susan Kim; Warren Chang
Journal:  CEN Case Rep       Date:  2013-12-17

3.  Gas6 regulates mesangial cell proliferation through Axl in experimental glomerulonephritis.

Authors:  M Yanagita; H Arai; K Ishii; T Nakano; K Ohashi; K Mizuno; B Varnum; A Fukatsu; T Doi; T Kita
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

4.  Meta-analysis of antiplatelet therapy for IgA nephropathy.

Authors:  Yoshinori Taji; Takashi Kuwahara; Satoru Shikata; Takeshi Morimoto
Journal:  Clin Exp Nephrol       Date:  2006-12-20       Impact factor: 2.801

Review 5.  Identifying and slowing progressive chronic renal failure.

Authors:  B Curtis; B J Barrett; A Levin
Journal:  Can Fam Physician       Date:  2001-12       Impact factor: 3.275

6.  Treatment of IgA nephropathy of adults presented by nephrotic syndrome.

Authors:  Senija Rasić; Snjezana Uncanin; Kenana Aganović; Ismar Rasić; Jasminka Dzemidzić; Alma Muslimović
Journal:  Bosn J Basic Med Sci       Date:  2008-08       Impact factor: 3.363

7.  Clinical assessment of low-dose steroid therapy for patients with IgA nephropathy: a prospective study in a single center.

Authors:  Minako Koike; Takashi Takei; Keiko Uchida; Kazuho Honda; Takahito Moriyama; Shigeru Horita; Tetsuya Ogawa; Takumi Yoshida; Ken Tsuchiya; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2008-02-21       Impact factor: 2.801

Review 8.  [IgA nephropathy: frequent, but rarely diagnosed].

Authors:  J Floege; H-J Gröne
Journal:  Internist (Berl)       Date:  2003-09       Impact factor: 0.743

Review 9.  Acute glomerulonephritis.

Authors:  C S Vinen; D B G Oliveira
Journal:  Postgrad Med J       Date:  2003-04       Impact factor: 2.401

Review 10.  [Therapy of vasculitides and vasculopathies].

Authors:  C Sunderkötter; K de Groot
Journal:  Hautarzt       Date:  2008-05       Impact factor: 0.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.